Asset Details
Do you wish to reserve the book?
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Do you wish to request the book?
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
晚期EGFR突变型非小细胞肺癌患者接受吉非替尼或厄洛替尼治疗的成本效益分析
2013
Overview
背景与目的非小细胞肺癌（non-small cell lung cancer,NSCLC）靶向治疗越来越受到关注，吉非替尼和厄洛替尼均被推荐用于存在表皮生长因子受体酪氨酸激酶（epidermal growth factor receptor,EGFR）基因突变的晚期NSCLC的一线治疗。本研究旨在分析比较吉非替尼和厄洛替尼在晚期NSCLC的疗效和生存获益，以及治疗成本效益。方法回顾性分析广州医保内的66例EGFR突变型的NSCLC患者。观察疗效和记录不良反应，定期随访生存预后，并追踪治疗费用。结果总共66例可评估患者，中位无进展生存期（progression-free survival,PFS）为15．0个月。其中吉非替尼49例，厄洛替尼17例，PFS分别为17．5个月和13．0个月（P=0．459）。皮疹发生率吉非替尼组为62．3％（31／49），厄洛替尼组为94．1％（16／17）。成本-效益比率（cost-effectiveness ratio,CER）吉非替尼组为3，027元／月，厄洛替尼组为6，800元／月，增量成本-效益比率（incremental cost-effectiveness ratio,ICEA）厄洛替尼为吉非替尼的2．25倍。结论EGFR突变的晚期NSCLC患者治疗，吉非替尼和厄洛替尼有相似的疗效和生存获益，前者不良反应可能较为轻微。广州医保下，吉非替尼成本-效益比率稍优。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.